Mergers & Acquisitions ·
Valion Bio receives unsolicited acquisition interest in CDMO Velocity Bioworks, weighs strategic options
TIVCValion Bio, Inc.
Valion Bio received unsolicited acquisition inquiries from independent third parties regarding its wholly owned contract development and manufacturing subsidiary, Velocity Bioworks. The company has entered preliminary discussions with interested parties while evaluating a range of strategic options for the unit, including a potential sale. Valion has retained an investment banking firm to advise the Board on these matters. Discussions remain preliminary, and no definitive agreement or commitment to sell has been reached. The company aims to maximize asset value while retaining production rights for its lead drug candidate, Entolimod. Valion Bio is a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways.